Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EMBC Embecta	$10.55 -6.3%	$11.98	$10.27 ▼ $21.48	$616.57M	1.24	464,799 shs	556,167 shs
FNA Paragon 28	$13.11 +0.1%	$13.07	$4.65 ▼ $13.13	$1.10B	1.47	1.13 million shs	19.38 million shs
LMAT LeMaitre Vascular	$81.01 -2.0%	$84.02	$71.42 ▼ $109.58	$1.83B	0.86	167,572 shs	165,768 shs
TMCI Treace Medical Concepts	$5.85 -3.9%	$7.09	$4.54 ▼ $10.79	$367.91M	0.79	605,542 shs	773,287 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EMBC Embecta	+5.04%	-8.38%	-5.22%	-19.11%	-14.24%
FNA Paragon 28	0.00%	0.00%	0.00%	+0.73%	+67.58%
LMAT LeMaitre Vascular	+1.57%	-2.44%	-9.75%	-19.77%	+3.67%
TMCI Treace Medical Concepts	+3.57%	-8.97%	-9.38%	-37.22%	+18.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EMBC Embecta	4.8249 of 5 stars	3.2	5.0	3.3	0.0	2.6	3.3	3.8
FNA Paragon 28	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LMAT LeMaitre Vascular	2.8459 of 5 stars	2.3	1.0	4.2	0.0	3.0	2.5	1.3
TMCI Treace Medical Concepts	2.3007 of 5 stars	3.1	1.0	0.0	0.0	2.3	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EMBC Embecta	2.33	Hold	$19.33	83.25% Upside
FNA Paragon 28	2.20	Hold	$12.75	-2.71% Downside
LMAT LeMaitre Vascular	2.63	Moderate Buy	$98.14	21.15% Upside
TMCI Treace Medical Concepts	2.29	Hold	$10.16	73.63% Upside

Current Analyst Ratings Breakdown

Latest FNA, EMBC, TMCI, and LMAT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/23/2025	EMBC Embecta	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$25.00
5/23/2025	EMBC Embecta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
5/9/2025	TMCI Treace Medical Concepts	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $8.60
4/11/2025	TMCI Treace Medical Concepts	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$9.50 ➝ $8.00
4/10/2025	EMBC Embecta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$15.00
4/9/2025	EMBC Embecta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
3/13/2025	TMCI Treace Medical Concepts	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$10.00 ➝ $9.50
3/3/2025	TMCI Treace Medical Concepts	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.40 ➝ $10.00
2/28/2025	LMAT LeMaitre Vascular	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$105.00 ➝ $110.00
2/28/2025	LMAT LeMaitre Vascular	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
2/28/2025	LMAT LeMaitre Vascular	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EMBC Embecta	$1.08B	0.57	$2.44 per share	4.32	($13.23) per share	-0.80
FNA Paragon 28	$256.18M	4.29	N/A	N/A	$2.05 per share	6.39
LMAT LeMaitre Vascular	$226.26M	8.09	$1.43 per share	56.52	$13.38 per share	6.05
TMCI Treace Medical Concepts	$210.82M	1.75	N/A	N/A	$2.24 per share	2.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EMBC Embecta	$78.30M	$0.90	10.55	3.44	0.78	5.25%	-19.22%	11.92%	8/8/2025 (Estimated)
FNA Paragon 28	-$57.53M	-$0.63	N/A	N/A	N/A	-25.31%	-37.90%	-18.22%	N/A
LMAT LeMaitre Vascular	$30.10M	$1.98	44.27	37.33	2.22	19.40%	13.15%	11.47%	8/7/2025 (Estimated)
TMCI Treace Medical Concepts	-$49.53M	-$0.85	N/A	N/A	N/A	-30.33%	-51.12%	-26.36%	8/5/2025 (Estimated)

Latest FNA, EMBC, TMCI, and LMAT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2025	Q2 2025	EMBC Embecta	$0.66	$0.70	+$0.04	$0.40	$261.77 million	$259.00 million
5/8/2025	Q1 2025	TMCI Treace Medical Concepts	-$0.31	-$0.25	+$0.06	-$0.25	$52.07 million	$52.57 million
5/1/2025	Q1 2025	LMAT LeMaitre Vascular	$0.50	$0.48	-$0.02	$0.48	$57.61 million	$59.87 million
3/6/2025	Q4 2024	FNA Paragon 28	-$0.12	-$0.13	-$0.01	-$0.13	$70.81 million	$71.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EMBC Embecta	$0.60	5.69%	N/A	66.67%	N/A
FNA Paragon 28	N/A	N/A	N/A	N/A	N/A
LMAT LeMaitre Vascular	$0.80	0.99%	+13.30%	40.40%	14 Years
TMCI Treace Medical Concepts	N/A	N/A	N/A	N/A	N/A

Latest FNA, EMBC, TMCI, and LMAT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/5/2025	EMBC Embecta	quarterly	$0.15	4.51%	5/28/2025	5/28/2025	6/13/2025
4/29/2025	LMAT LeMaitre Vascular	quarterly	$0.20	1%	5/15/2025	5/15/2025	5/29/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EMBC Embecta	N/A	2.24	1.67
FNA Paragon 28	0.79	3.50	1.60
LMAT LeMaitre Vascular	N/A	7.74	5.52
TMCI Treace Medical Concepts	0.51	4.12	2.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EMBC Embecta	93.83%
FNA Paragon 28	63.57%
LMAT LeMaitre Vascular	84.64%
TMCI Treace Medical Concepts	84.08%

Insider Ownership

Company	Insider Ownership
EMBC Embecta	0.42%
FNA Paragon 28	15.32%
LMAT LeMaitre Vascular	9.50%
TMCI Treace Medical Concepts	27.72%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EMBC Embecta	1,900	58.44 million	57.89 million	Optionable
FNA Paragon 28	343,000	83.94 million	70.89 million	Optionable
LMAT LeMaitre Vascular	490	22.59 million	20.06 million	Optionable
TMCI Treace Medical Concepts	250	62.89 million	47.08 million	Optionable

FNA, EMBC, TMCI, and LMAT Headlines

Recent News About These Companies

Investor Alert: Deadline Approaching to Join Treace Medical Concepts, Inc. (TMCI) Class Action – Contact Levi & Korsinsky

May 28 at 4:30 PM | accessnewswire.com

Class Action Filed Against Treace Medical Concepts, Inc. (TMCI) Over Securities Violations - Contact Levi & Korsinsky Today

May 28 at 2:45 PM | accessnewswire.com

TMCI DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Treace Medical Concepts, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action – TMCI

May 28 at 2:23 PM | globenewswire.com

Levi & Korsinsky Notifies Treace Medical Concepts, Inc. (TMCI) Shareholders of Class Action Lawsuit and June 10, 2025 Deadline

May 28 at 12:15 PM | accessnewswire.com

Treace Medical Concepts, Inc. (TMCI) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

May 28 at 12:00 PM | prnewswire.com

Shareholders of Treace Medical Concepts, Inc. (TMCI): Protect Your Rights Before June 10, 2025 - Contact Levi & Korsinsky

May 28 at 10:45 AM | accessnewswire.com

Recover Investment Losses: Levi & Korsinsky Files Class Action Against Treace Medical Concepts, Inc. (TMCI)

May 28 at 7:15 AM | accessnewswire.com

TMCI SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Treace Medical Concepts, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!

May 28 at 7:00 AM | accessnewswire.com

TMCI LAWSUIT ALERT: Levi & Korsinsky Notifies Treace Medical Concepts, Inc. Investors - Lead Plaintiff Deadline June 10, 2025

May 27 at 4:30 PM | accessnewswire.com

ROSEN, A LEADING LAW FIRM, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TMCI

May 27 at 4:12 PM | markets.businessinsider.com

Class Action Alert: Levi & Korsinsky Reminds Treace Medical Concepts, Inc. (TMCI) Investors of June 10, 2025 Deadline

May 27 at 2:40 PM | accessnewswire.com

ROSEN, A LEADING LAW FIRM, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TMCI

May 27 at 2:23 PM | accessnewswire.com

Investors Urged to Contact Levi & Korsinsky for Information Before June 10, 2025 - Treace Medical Concepts, Inc. (TMCI)

May 27 at 12:30 PM | accessnewswire.com

TMCI ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Treace Medical Concepts, Inc. - June 10, 2025 Deadline

May 27 at 11:00 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Treace Medical Concepts, Inc of Class Action Lawsuit and Upcoming Deadlines - TMCI

May 27 at 10:45 AM | accessnewswire.com

Treace Medical Concepts, Inc. (TMCI) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of June 10, 2025 Deadline

May 27 at 9:30 AM | accessnewswire.com

Securities Lawsuit Alert: Treace Medical Concepts, Inc. (TMCI) - Contact Levi & Korsinsky Before June 10, 2025

May 27 at 8:45 AM | accessnewswire.com

TREACE MEDICAL CONCEPTS, INC. (NASDAQ: TMCI) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Treace Medical Concepts, Inc. Investors of Upcoming Deadline

May 27 at 8:30 AM | globenewswire.com

Investor Alert: Deadline Approaching to Join Treace Medical Concepts, Inc. (TMCI) Class Action - Contact Levi & Korsinsky

May 27 at 7:25 AM | accessnewswire.com

TMCI INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Treace Medical Concepts, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

May 27 at 7:00 AM | accessnewswire.com

BNP Paribas Financial Markets Makes New $590,000 Investment in Treace Medical Concepts, Inc. (NASDAQ:TMCI)

May 26 at 3:21 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FNA, EMBC, TMCI, and LMAT Company Descriptions

Embecta NASDAQ:EMBC

$10.55 -0.71 (-6.31%)

Closing price 04:00 PM Eastern

Extended Trading

$10.75 +0.20 (+1.90%)

As of 07:56 PM Eastern

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

Paragon 28 NYSE:FNA

$13.10 +0.02 (+0.11%)

Closing price 04/17/2025

Extended Trading

$13.10 0.00 (0.00%)

As of 04/17/2025 05:47 PM Eastern

Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

LeMaitre Vascular NASDAQ:LMAT

$81.01 -1.67 (-2.02%)

Closing price 04:00 PM Eastern

Extended Trading

$81.02 +0.01 (+0.01%)

As of 04:10 PM Eastern

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Treace Medical Concepts NASDAQ:TMCI

$5.85 -0.24 (-3.94%)

Closing price 04:00 PM Eastern

Extended Trading

$5.85 0.00 (0.00%)

As of 04:04 PM Eastern

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time